论文部分内容阅读
利拉鲁肽和阿必鲁泰是治疗2型糖尿病的新靶点药物,较已有的口服降糖药降糖效果好、副作用较小,而且可以减轻体质量,因此有广阔的应用前景。作为新一代降糖新药,利拉鲁肽是一种短效胰高血糖素样肽-1(GLP-1)类似物,阿必鲁泰是一种长效GLP-1类似物,两者既有共同之处,又有区别。总结这二种抗糖尿病新药的临床应用和不良反应研究进展,为临床合理用药以及新药研发提供思路。
Liraglutide and Arbitux are new target drugs for the treatment of type 2 diabetes. Compared with the existing oral hypoglycemic agents, hypoglycemic agents have good hypoglycemic effect, less side effects, and can reduce body weight, thus having broad application prospects. As a new generation of hypoglycemic agents, liraglutide is a short-acting glucagon-like peptide-1 (GLP-1) analog that is a long-acting GLP-1 analogue, both There are commonalities, there are differences. Summary of clinical application of these two new anti-diabetic drugs and adverse reactions of research, clinical rational drug use and research and development to provide ideas.